「ex」の検索結果
135件：11～15件目を表示
-
千寿製薬株式会社
NEWS & RELEASE December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Pot
http://www.senju.co.jp/english/ -
发表论文 | 研究与开发 | 千寿制药株式会社
factor signaling pathway Momoko Kobayashi-Otsugu, Yayoi Kishimoto, Mitsuyoshi Azuma, Chiho Fukiage Experimental Eye Research Stability of Sodium Pentobarbital 5w/v% Aqueous Solution During Short-Term...
http://www.senju.co.jp/chinese/rd/thesis/ -
学会发表 | 研究与开发 | 千寿制药株式会社
lt Lake City, Utah, United States of America Effects of a novel TRPV1 antagonist, SJP-0132, on CCL5 expression in corneal epithelial cells Yuya Atsumi, Toshizo Sato, Atsuhiro Kanda ARVO 2025 開催日：2025年...
http://www.senju.co.jp/chinese/rd/society/ -
おける点眼慢性毒性及び眼粘膜刺激試験). 1982. 58) 中桐直人ほか：応用薬理. 1979; 17(4): 663-671. 59) Tanaka, N. et al.：J Pharmacol Exp Ther. 1983; 224(2): 424-430. (PMID: 6822964) 2．その他の参考文献 該当資料なし XII．参考資料 －34－ XII．参考資料 1．主な外国での発売...
https://www.senju.co.jp/system/files/2022-03/20220330_MKLA_IF_0.PDF -
g less than 50,000 patients in Japan, with particularly high medical needs. This designation can be expected to shorten the period required for regulatory approval, resulting in early approval and lau...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240708_0.pdf